L Number	Hits	Search Text	DB	Time stamp
1	193	MP52	USPAT;	2004/09/08 17:12
			US-PGPUB; EPO; JPO; DERWENT	
2	19	MP52.clm.	USPAT; US-PGPUB; EPO; JPO;	2004/09/08 17:12
3	12	crystallographically WITH calcium	DERWENT USPAT; US-PGPUB; EPO; JPO;	2004/09/08 17:15
4	0	MP52 and (crystallographically WITH calcium)	DERWENT USPAT; US-PGPUB; EPO; JPO;	2004/09/08 17:16
5	11	(MP52 and bone) and crystal\$8	DERWENT USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/09/08 17:17
6	19	PAULISTA NEAR MICHAEL	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/09/08 17:17
7	39	(US-5994094-\$ or US-5658882-\$ or US-6409764-\$ or US-6328963-\$ or US-5700289-\$ or US-5691397-\$ or US-5522893-\$ or US-5506303-\$ or US-55262166-\$ or US-5171326-\$ or US-5149368-\$ or US-5137534-\$ or US-5135394-\$ or US-4655777-\$ or US-6120760-\$ or US-4655777-\$ or US-6120760-\$ or US-5801014-\$ or US-6531450-\$ or US-6727224-\$).did. or (US-20020102633-\$ or US-20020045568-\$ or US-20010016646-\$ or US-20020055143-\$).did. or (WO-9966060-\$ or EP-866125-\$ or WO-9833514-\$ or WO-9704095-\$ or WO-97031098-\$).did. or (JP-2000004882-\$ or JP-09031098-\$).did. or (WO-9961611-\$ or WO-9833514-\$ or WO-9741250-\$ or WO-9706254-\$ or WO-9741250-\$ or WO-9706254-\$ or WO-9704095-\$).did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/09/08 17:19
	3462	424/93.\$2.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/10/15 12:55
-	250	424/93.\$2.ccls. and bone.clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/10/15 12:56
_	147	(424/93.\$2.ccls. and bone.clm.) and matrix	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/10/15 12:57
_	103	((424/93.\$2.ccls. and bone.clm.) and matrix) and (calcium or tricalcium)	USPAT; US-PGPUB; EPO; JPO;	2002/10/15 12:57
_	22	(424/93.\$2.ccls. and bone.clm.) and (matrix WITH (calcium or tricalcium))	DERWENT USPAT; US-PGPUB; EPO; JPO;	2002/10/15 12:58
~	1067	bone ADJ morphogenic ADJ protein	DERWENT USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/10/15 13:14

_	2	(bone ADJ morphogenic ADJ protein) and	USPAT;	2002/10/15 13:14
		(calcium NEAR matrix)	US-PGPUB;	
			EPO; JPO;	
			DERWENT	
_	36	(MP52 and bone) and calcium	USPAT;	2004/09/08 17:16
			US-PGPUB;	
			EPO; JPO;	
	2.7	(10050 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	DERWENT	2002/10/15 12:24
_	37	(MP52 and bone) and (calcium or	USPAT;	2002/10/15 13:24
		tricalcium)	US-PGPUB;	ļ
			EPO; JPO; DERWENT	
	26	((MP52 and bone) and (calcium or	USPAT;	2002/10/15 13:25
_	26	tricalcium)) and pure	US-PGPUB;	2002/10/13 13.23
		cricarcram, and pure	EPO; JPO;	
			DERWENT	
_	330	alpha-tricalcium or beta-tricalcium	USPAT;	2002/10/15 13:29
		alpha clicaloram of sour clical	US-PGPUB;	
			EPO; JPO;	
			DERWENT	
_	6	(alpha-tricalcium or beta-tricalcium)	USPAT;	2002/10/15 13:26
		WITH matrix	US-PGPUB;	
			EPO; JPO;	
			DERWENT	
-	116	(alpha-tricalcium or beta-tricalcium) and	USPAT;	2002/10/15 13:30
		bone.clm.	US-PGPUB;	,
			EPO; JPO;	
			DERWENT	
-	108	((alpha-tricalcium or beta-tricalcium) and	USPAT;	2002/10/15 13:52
		bone.clm.) and (matrix or composition or	US-PGPUB;	
		support)	EPO; JPO;	
			DERWENT	
-	8	((424/93.\$2.ccls. and bone.clm.) and	USPAT;	2002/10/15 13:54
		(matrix WITH (calcium or tricalcium)))	US-PGPUB;	
		and pure	EPO; JPO;	
			DERWENT	0000/10/15 13 54
_	0	((424/93.\$2.ccls. and bone.clm.) and	USPAT;	2002/10/15 13:54
	1	(matrix WITH (calcium or tricalcium)))	US-PGPUB;	
		and phase-pure	EPO; JPO; DERWENT	
_	2	("6120760").PN.	USPAT;	2002/10/15 15:19
		0120700 7:114:	US-PGPUB;	2002/10/13 13:13
			EPO; JPO;	
			DERWENT	
_	146	GDF-5 GDF5 MP52 MP-52	USPAT;	2002/10/15 17:09
			US-PGPUB;	' ', = '
			EPO; JPO;	
			DERWENT	
-	106	(GDF-5 GDF5 MP52 MP-52	USPAT;	2002/10/15 16:59
) and (bone or cartilage)	US-PGPUB;	
			EPO; JPO;	
			DERWENT	
-	22	(GDF-5 GDF5 MP52 MP-52).clm.	USPAT;	2002/10/15 17:05
			US-PGPUB;	
			EPO; JPO;	
	_ [DERWENT	0000/40/15
-	5	WO ADJ "9504819"	USPAT;	2002/10/15 17:40
			US-PGPUB;	
			EPO; JPO;	
I _	106	MP52 and bone	DERWENT	2002/00/20 12:25
-	100	MESZ did Dolle	USPAT; US-PGPUB;	2003/09/29 12:35
			EPO; JPO;	
			DERWENT	
_	70	(MP52 and bone) and matri\$10	USPAT;	2003/09/29 12:35
	'	The state of the materials	US-PGPUB;	
			EPO; JPO;	
			DERWENT	
				L

```
(FILE 'HOME' ENTERED AT 17:23:06 ON 08 SEP 2004)
     FILE 'MEDLINE' ENTERED AT 17:23:23 ON 08 SEP 2004
L1
              1 S MP52
     FILE 'MEDLINE, AGRICOLA, CANCERLIT, SCISEARCH, CAPLUS, MEDICONF' ENTERED
     AT 17:24:00 ON 08 SEP 2004
L2
             40 S MP52
1.3
             39 DUP REM L2 (1 DUPLICATE REMOVED)
L4
             24 S L3 AND (BONE OR CARTILAGE)
              3 S L3 AND (CALCIUM OR MATRIX OR CRYSTALLOGRAPHIC?)
L_5
             24 SORT L4 PY
L6
                E PAULISTA MICHAEL?/AU
             10 S E2
L7
              3 S L7 AND L2
L8
=> d an ti so au ab pi 18 1-3
     ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
L8
ΑN
     1998:335063 CAPLUS
DN
     129:32362
     Compositions with improved cartilage- and/or bone-inducing activity
TI
     Ger. Offen., 12 pp.
SO
     CODEN: GWXXBX
ΤN
     Paulista, Michael; Pohl, Jens; Pabst, Joachim; Heide, Helmut
     A bioactive implant material with cartilage- and/or bone-inducing activity
AB
     comprises (A) s bone- and/or cartilage-inducing protein or protein mixture
     and (B) a microporous Ca phosphate ceramic carrier matrix with
     interconnecting pores, which has inherent bone-inducing activity.
     inducing protein preferably belongs to the TGF-$\beta$ superfamily, especially
     protein MP52. The implant material is useful for treatment of
     cartilage and/or bone damage or diseases (no data).
                         KIND DATE
                                             APPLICATION NO.
     PATENT NO.
                         A1
                                 19980520
                                            DE 1996-19647853
PI
     DE 19647853
                                                                      19961119
     WO 9821972
                          A2
                                 19980528
                                              WO 1997-EP6463
                                                                      19971119
                                 19980917
     WO 9821972
                           A3
         W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
         PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
             GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
             GN, ML, MR, NE, SN, TD, TG
     AU 9855533
                          A1
                                 19980610
                                              AU 1998-55533
                                                                      19971119
     EP 942758
                           A2
                                 19990922
                                              EP 1997-951919
                                                                      19971119
     EP 942758
                           B1
                                 20040114
         R: DE, ES, FR, GB, IT
                           T2
                                 20010417
     JP 2001505097
                                              JP 1998-523215
                                                                      19971119
                           T3
                                 20040701
     ES 2210592
                                              ES 1997-951919
                                                                      19971119
L8
     ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN
     1997:145191 CAPLUS
DN
     126:139895
TΙ
     Use of protein MP52 for prevention and treatment of nervous
     system disorders
SO
     Ger. Offen., 21 pp.
     CODEN: GWXXBX
IN
     Hoetten, Gertrud; Pohl, Jens; Bechtold, Rolf; Paulista, Michael;
     Unsicker, Klaus
     Protein MP52, a growth and differentiation factor of the
AB
     TGF-\beta superfamily, and fragments and fusion proteins thereof are
     useful for prevention and treatment of nervous system disorders and
     neuropathol. conditions caused by aging of the nervous system.
     MP52 improves the survival of dopaminergic neurons, at least
     partially through an action on the associated astrocytes. Thus, MP52
```

DNA on a vaccinia virus vector was expressed in 143B cells, and MP52 DNA on prokaryotic vector pBP2 was expressed in Escherichia coli, purified by reversed-phase HPLC, and refolded at pH 8-10. Transcription of MP52 DNA was observed in mouse brain and rat spinal cord.

		ENT	_				_			-		LICAT					ATE	
PI	DE	1952 9703	5416			A1		1997	0116 0130	Ι	Œ	1995 - 1996 -	1952	5416		19	9950. 9950.	
		9703	188			A 3		1997	0227									
		W :	ES,	FI, LU,	GB,	GE,	HU,	IL,	IS,	JP,	KE	, CA, , KG, , NO,	KP,	KR,	KZ,	LK,	LR,	LS,
		RW:	KE,	LS,								DE,	•				GB,	GR,
	AU	9666	151			A1		1997	0210	I	U/	1996-	6615	1		19	9960	712
	ZA	9605938			Α	A 19970217			ZA 1996-5938					19960712				
	EΡ	8379	38			A2		1998	0429	F	ΞP	1996-	9257	40		19	9960	712
		R:	DE,	ES,	FR,	GB,	IT											
	JP	1150	9097			T2		1999	0817	Ċ	JΡ	1996-	5055	11		15	9960'	712
	US	JS 2002045568			A1		2002	0418	τ	JS	1998-	9814	90		19	9980	518	
	US	6531	450			B2		2003	0311									
	US	2003	22024	18		A1		2003	1127	Į	JS	2003-	3565	13		20	0030	203

- L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
- AN 1995:464505 CAPLUS
- DN 122:231763
- TI A new growth/differentiation factor from the transforming growth factor $\boldsymbol{\beta}$ family
- SO Ger. Offen., 20 pp.

CODEN: GWXXBX

- IN Hoetten, Gertrud; Neidhardt, Helge; Paulista, Michael
- AB A new member of the TGF- β family of growth/differentiation factors (MP-52) and a cDNA and the gene encoding it are described. A partial cDNA was obtained by PCR using amino acid sequence-derived primers and this was used to screen a com. human gene bank to obtain the gene. Expression of the cDNA in animal cells is using vaccinia and bovine papillomavirus vectors is demonstrated. The protein was found to have.

		TENT NO.			KINI	D DATE	APPLICATION NO.		
ΡI	DE						DE 1994-4420157	19940609	
	CA	2169171			AA	19950216	CA 1994-2169171	19940809	
	WO	9504819			A1	19950216	WO 1994-EP2630	19940809	
		W: AU,	BY,	CA,	CN,	CZ, HU, JP,	KR, LT, NZ, RU, SI,	UA, VN	
		RW: AT,	BE,	CH,	DE,	DK, ES, FR,	GB, GR, IE, IT, LU,	MC, NL, PT, SE	
	AU	9474986			A1	19950228	AU 1994-74986	19940809	
		688362							
		713529					EP 1994-924856	19940809	
	EΡ	713529			В1	20000202			
							GB, GR, IE, IT, LI,		;
	CN	1129013			Α	19960814	CN 1994-193027	19940809	
	HU	74271			A2	19961128	HU 1995-3853	19940809	
		219504							
	JP	09501053			T2	19970204	JP 1994-506226		
		189475			\mathbf{E}		AT 1994-924856	19940809	
		2142953					ES 1994-924856		
	PT	713529			Т	20000630	PT 1994-924856	19940809	
		2157406			C2		RU 1996-104372		
	CZ	288795			В6	20010912	CZ 1996-357		
	z_{A}	9405992			Α				
	US	5994094			Α		US 1994-288508		
	TW	448183					TW 1994-83108337		
	US	6764994			B 1		US 1999-386450		
	GR	3032628			T 3	20000531	GR 2000-400326	20000210	

US 2004146979 A1 20040729 US 2004-800917 20040316

```
(FILE 'HOME' ENTERED AT 17:23:06 ON 08 SEP 2004)
     FILE 'MEDLINE' ENTERED AT 17:23:23 ON 08 SEP 2004
               1 S MP52
L1
     FILE 'MEDLINE, AGRICOLA, CANCERLIT, SCISEARCH, CAPLUS, MEDICONF' ENTERED
     AT 17:24:00 ON 08 SEP 2004
L2
              40 S MP52
              39 DUP REM L2 (1 DUPLICATE REMOVED)
L3
              24 S L3 AND (BONE OR CARTILAGE)
1.4
               3 S L3 AND (CALCIUM OR MATRIX OR CRYSTALLOGRAPHIC?)
1.5
              24 SORT L4 PY
L6
=> d an ti so au ab pi 16 10 3 7 8 9 12 23
     ANSWER 10 OF 24 CAPLUS COPYRIGHT 2004 ACS on STN
L<sub>6</sub>
     1998:335063 CAPLUS
AN
DN
     129:32362
     Compositions with improved cartilage- and/or bone
     -inducing activity
SO
     Ger. Offen., 12 pp.
     CODEN: GWXXBX
     Paulista, Michael; Pohl, Jens; Pabst, Joachim; Heide, Helmut
TN
     A bioactive implant material with cartilage- and/or bone
     -inducing activity comprises (A) s bone- and/or
     cartilage-inducing protein or protein mixture and (B) a microporous
     Ca phosphate ceramic carrier matrix with interconnecting pores, which has
     inherent bone-inducing activity. The inducing protein
     preferably belongs to the TGF-\beta superfamily, especially protein
     MP52. The implant material is useful for treatment of
     cartilage and/or bone damage or diseases (no data).
     PATENT NO.
                           KIND
                                  DATE
                                               APPLICATION NO.
                                                                         DATE
                           ----
     DE 19647853
                           A1
                                   19980520
                                             DE 1996-19647853
                                                                         19961119
PΤ
                                                                         19971119
     WO 9821972
                            A2
                                   19980528
                                                WO 1997-EP6463
                                   19980917
     WO 9821972
                           A3
         W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR,
              KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
              PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
         US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
              GN, ML, MR, NE, SN, TD, TG
     AU 9855533
                            A1
                                   19980610
                                                AU 1998-55533
                                                                         19971119
                                                                         19971119
                                   19990922
                                                EP 1997-951919
     EP 942758
                            A2
                                   20040114
     EP 942758
                            В1
         R: DE, ES, FR, GB, IT
     JP 2001505097
                                                JP 1998-523215
                                   20010417
                                                                         19971119
                            Т2
                                                                         19971119
     ES 2210592
                            Т3
                                   20040701
                                                ES 1997-951919
     ANSWER 3 OF 24 CAPLUS COPYRIGHT 2004 ACS on STN
1.6
ΑN
     1996:732173 CAPLUS
DN
     126:1703
     Recombinant preparation of dimeric human protein MP52 and use
TΙ
     for treating bone diseases
SO
     PCT Int. Appl., 33 pp.
     CODEN: PIXXD2
     Makishima, Fusao; Takamatsu, Hiroyuki; Miki, Hideo; Kawai, Shinji; Kimura,
     Michio; Matsumoto, Tomoaki; Katsuura, Mieko; Enomoto, Koichi; Satoh,
```

Methods for recombinant preparation of mature monomeric human protein MP52 (119 amino acids) in transgenic Escherichia coli followed by

dimer on stimulating the growth of bones or cartilage

cartilage and bone diseases.

chemical dimerization of the protein are disclosed. Biol. effects of the

were also demonstrated. This dimer protein is useful in the treatment of

```
PATENT NO.
                         KIND
                                 DATE
                                             APPLICATION NO.
                                                                     DATE
                          ----
                                 -----
                                              ______
                                            WO 1996-JP1062
                                19961024
                         A1
PT
     WO 9633215
         W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KR,
             LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK,
         TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
             MR, NE, SN, TD, TG
                                 19961024
                                              CA 1996-2216741
                                                                      19960419
     CA 2216741
                          AA
                                              AU 1996-53470
                                                                      19960419
     AU 9653470
                           A1
                                 19961107
     AU 704515
                          B2
                                 19990422
                                 19980715
                                              CN 1996-194702
                                                                      19960419
     CN 1187824
                          Α
                                              EP 1996-910198
                                 19991110
                                                                      19960419
     EP 955313
                          A1
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
             SI, FI
                                              BR 1996-8019
                                                                      19960419
     BR 9608019
                                 19991130
                           Α
                          B2
                                 20000111
                                              JP 1996-531621
                                                                      19960419
     JP 2997549
                                              AP 1997-1138
                                                                      19960419
     AP 856
                           Α
                                 20000712
         W: KE, LS, MW, SD, SZ, UG
     PL 186518 B1
                                 20040130
                                              PL 1996-322945
                                                                      19960419
                                              NO 1997-4812
                                                                      19971017
                                 19971219
     NO 9704812
                           Α
                                              US 1997-945459
     US 2002102633
                           A1
                                 20020801
                                                                      19971209
     US 2003181378
                          A1
                                 20030925
                                              US 2003-365231
                                                                      20030212
     ANSWER 7 OF 24 CAPLUS COPYRIGHT 2004 ACS on STN
L6
ΑN
     1997:244334 CAPLUS
DN
     126:221079
     Human MP52 protein, its manufacture with recombinant cells, and
TΙ
     its use in pharmaceuticals
     PCT Int. Appl., 25 pp.
SO
     CODEN: PIXXD2
     Kimura, Michio; Matsumoto, Tomoaki; Takahashi, Mikiko; Kawai, Shinji;
TN
     Fujino, Yukio
     This invention relates to a human MP52 Arg and a pharmaceutical
AB
     medical composition inter alia for promoting cartilage and
     bone morphogenation comprising human MP52 Arg. In
     particular, the medical composition is useful for treating bone
     disease caused by abnormal bone metabolism such as osteoporosis, for
     treating bone fracture and for the purpose of orthopedic
     reconstruction, bone transplantation, cosmetic surgery and
     dental therapeutics. Further, it is useful for treating cartilage
     disorders. Recombinant CHO cells expressing prepro-human MP42 were prepared
     and cultured to obtain recombinant MP52. Treatment of ROB-C26
     cells with the MP52 increased total alkaline phosphatase activity in
     a concentration-dependent manner.
     PATENT NO.
                         KIND DATE
                                              APPLICATION NO.
                          ----
                                  -----
                                             WO 1996-EP3427
                                19970220
                                                                      19960802
     WO 9706254
                          A1
PΙ
         W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR,
              LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,
              SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
         RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM
                                              ZA 1996-6489
     ZA 9606489
                                 19970226
                                                                      19960731
                          Α
                                  19970220
                                              CA 1996-2227204
     CA 2227204
                           AA
                                                                      19960802
                                              AU 1996-67891
     AU 9667891
                           A1
                                  19970305
                                                                      19960802
     AU 699708
                           B2
                                  19981210
                                              EP 1996-928406
     EP 842274
                           A1
                                  19980520
                                                                      19960802
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
     CN 1192237 A
                                 19980902 CN 1996-195841 19960802
                                              BR 1996-9983
     BR 9609983
                           Α
                                 19990112
                                                                      19960802
     JP 2000511155
                           T2
                                 20000829
                                              JP 1997-508115
                                                                      19960802
                                 19980128
                                              NO 1998-375
                                                                      19980128
     NO 9800375
     ANSWER 8 OF 24 CAPLUS COPYRIGHT 2004 ACS on STN
L6
     1997:230835 CAPLUS
```

ΑN

```
DN
    126:207826
ΤI
    Recombinant preparation of human protein MP52 for medical and
    cosmetic applications
    Jpn. Kokai Tokkyo Koho, 24 pp.
    CODEN: JKXXAF
    Kimura, Michio; Matsumoto, Tomoaki; Takahashi, Mikiko; Kawai, Shinji;
IN
    Fujino, Yukio
    High-mol.-weight human protein MP52 (HMW MP52), a growth
AR
    and differentiation factor of the TGF-\beta superfamily, is prepared by
    expression of its encoding DNA sequences in transgenic animal cells. HMW
    MP52 consists of dimers of entire HMW MP52 (501 amino
    acids) or its fragments. Its uses for orthopedic reconstruction,
    bone implantation, cosmetic surgery, dental implantation, etc.,
    are claimed.
     PATENT NO.
                        KIND
                             DATE
                                          APPLICATION NO.
                                                                 DATE
     -----
                        ----
                               _____
                       A2
                                          JP 1995-218022
PΙ
    JP 09031098
                               19970204
                                                                 19950724
                                        WO 1996-JP2065
    WO 9704095
                         A1
                               19970206
                                                                 19960724
        W: AU, CA, CN, HU, KR, MX, NO, NZ, RU, UA, US
        RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, NL, PT, SE
    CA 2224289
                        AA
                               19970206
                                         CA 1996-2224289 19960724
                               19970218
                                          AU 1996-65304
                                                                 19960724
                        Α1
    AU 9665304
                               19990422
    AU 704364
                         B2
    EP 866125
                        A1
                               19980923
                                         EP 1996-925064
                                                                 19960724
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
                                                           19960724
                      Α
                             19981014
                                          CN 1996-196950
     CN 1196087
    NO 9800300
                               19980123
                                          NO 1998-300
                                                                 19980123
                         Α
    ANSWER 9 OF 24 CAPLUS COPYRIGHT 2004 ACS on STN
L6
    1998:542980 CAPLUS
AN
DN
TI
    Freeze-dried composition of bone morphogenetic protein human
SO
    PCT Int. Appl., 10 pp.
    CODEN: PIXXD2
IN
    Inagaki, Mitsuko; Ichikawa, Hideki
    The invention relates to a stable freeze-dried composition of a bone
AΒ
    morphogenetic protein human MP52 wherein coloration and
     shrinking of MP52 during storage and aggregation at the
     re-dissoln. can be prevented. The composition is obtained by mixing
    MP52 with mannitol at a weight ratio of 1 : 5 to 1 : 50 followed by
     freeze-drying.
    PATENT NO.
                        KIND DATE
                                         APPLICATION NO.
                                                                DATE
                                        WO 1998-JP371
PΙ
    WO 9833514
                        A1
                              19980806
                                                                19980129
        W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL,
            IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO,
            SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ,
        MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
            FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
            GA, GN, ML, MR, NE, SN, TD, TG
                                          AU 1998-56791
    AU 9856791
                        A1
                               19980825
                                                                 19980129
    AII 737595
                        B2
                               20010823
    EP 972520
                        A1
                               20000119
                                          EP 1998-901044
                                                                 19980129
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
    BR 9807537
                               20000321
                                          BR 1998-7537
                        Α
                                                                19980129
    NZ 336509
                         Α
                               20010330
                                          NZ 1998-336509
                                                                 19980129
    AP 983
                        Α
                               20010716
                                          AP 1999-1602
                                                                 19980129
        W: GH, GM, KE, LS, MW, SD, SZ, UG, ZW
    MX 9906784
                A
                               20000731
                                          MX 1999-6784
                                                                 19990721
    NO 9903702
                        Α
                               19990929
                                          NO 1999-3702
                                                                 19990729
    US 2004132653
                        A1
                               20040708
                                          US 2003-666535
                                                                 20030922
    ANSWER 12 OF 24 CAPLUS COPYRIGHT 2004 ACS on STN
L6
```

AN

DN

1999:764189 CAPLUS

132:9630

Expression of mutant recombinant human MP52 protein monomer with bone morphogenetic activity and its use for preventing and

```
PCT Int. Appl., 26 pp.
SO
     CODEN: PIXXD2
     Kawai, Shinji; Kimura, Michio; Muraki, Yoshifumi; Katsuura, Mieko
IN
     A mutant recombinant human MP52 protein monomer belonging to
     TGF-\beta superfamily with two-fold higher activity for inducing
     osteoblast cell line differentiation was created by site-directed
     mutagenesis replacing a cysteine contributing to dimer formation with
     another amino acid. Another amino acid replacing a cysteine can be
     serine, threonine, alanine, or valine, and preferably alanine. The mutant
     recombinant protein can be expressed in Escherichia coli, yeast, insect
     cells, and mammalian cells that have been transformed with an expression
     vector having a DNA sequence coding for the monomer protein. The use of
     the mutant recombinant human MP52 protein monomer for prevention
     and therapeutic treatment of bone and/or cartilage
     diseases such as osteoporosis, osteoarthritis or arthrosteitis,
     bone fracture, and lack of teeth root or tooth socket is claimed.
                                            APPLICATION NO.
     PATENT NO.
                         KIND
                               DATE
                         ----
                                19991202 WO 1999-IB866
PΙ
     WO 9961611
                          A1
             AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU,
             ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX,
             NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
             ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
             CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     JP 11335398
                          A2
                                19991207
                                             JP 1998-141379
                                                                     19980522
                                 19991213
                                             AU 1999-35309
                                                                     19990514
     AU 9935309
                          A1
                                             EP 1999-917029
     EP 1078054
                          Α1
                                 20010228
                                                                     19990514
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
     JP 2002516098
                          T2
                                 20020604
                                             JP 2000-550995
                                                                     19990514
L6
     ANSWER 23 OF 24 CAPLUS COPYRIGHT 2004 ACS on STN
AN
     2004:550724 CAPLUS
DN
     141:76794
     Lyophilized composition of bone morphogenetic factor human
TI
SO
     U.S. Pat. Appl. Publ., 4 pp., Cont.-in-part of U.S. Ser. No. 355,551,
     abandoned.
     CODEN: USXXCO
IN
     Ichikawa, Hideki; Inagaki, Mitsuko
AB
     By mixing bone morphogenetic factor human MP52 with
     mannitol at a weight ratio of 1:5-50, followed by lyophilization, a stable
     lyophilized composition of bone morphogenetic factor human
     MP52 is obtained which prevents coloring and atrophy of the
     lyophilized product of bone morphogenetic factor human
     MP52 during storage and also prevents cohesion at the time of
     reconstitution. To 1 mg/mL of an aqueous solution of purified rhMP52, 10, 25,
     and 50 mg, D-mannitol was added. After the resulting mixture was filtered
     through a 0.22-µm membrane filter, 1 mL portions of the filtrate so
     obtained were filled in vials in a sterile fashion. They were
     lyophilized, whereby a composition of the present invention was prepared in the
     form of pharmaceutical product.
                                             APPLICATION NO.
     PATENT NO.
                        KIND
                                DATE
                                                                    DATE
     . . . . . . . . . . .
                         ----
                                 -----
                                             ------
     US 2004132653
                                20040708
                                             US 2003-666535
рτ
                         A1
                                                                    20030922
     WO 9833514
                          A1
                                19980806
                                             WO 1998-JP371
                                                                    19980129
         W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL,
             IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ,
             MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
             FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
             GA, GN, ML, MR, NE, SN, TD, TG
```

treating cartilage and bone diseases

=>